227 related articles for article (PubMed ID: 16652370)
1. Anti-angiogenic drugs: from bench to clinical trials.
Quesada AR; Muñoz-Chápuli R; Medina MA
Med Res Rev; 2006 Jul; 26(4):483-530. PubMed ID: 16652370
[TBL] [Abstract][Full Text] [Related]
2. Angiogenesis--a new target for future therapy.
Pandya NM; Dhalla NS; Santani DD
Vascul Pharmacol; 2006 May; 44(5):265-74. PubMed ID: 16545987
[TBL] [Abstract][Full Text] [Related]
3. Microtubule-targeting agents in angiogenesis: where do we stand?
Pasquier E; Honoré S; Braguer D
Drug Resist Updat; 2006; 9(1-2):74-86. PubMed ID: 16714139
[TBL] [Abstract][Full Text] [Related]
4. Design and development of polymer conjugates as anti-angiogenic agents.
Segal E; Satchi-Fainaro R
Adv Drug Deliv Rev; 2009 Nov; 61(13):1159-76. PubMed ID: 19699248
[TBL] [Abstract][Full Text] [Related]
5. Combination of anti-angiogenic therapy and virotherapy: arming oncolytic viruses with anti-angiogenic genes.
Tysome JR; Lemoine NR; Wang Y
Curr Opin Mol Ther; 2009 Dec; 11(6):664-9. PubMed ID: 20072943
[TBL] [Abstract][Full Text] [Related]
6. Angiogenesis inhibitors in cancer therapy.
Dredge K; Dalgleish AG; Marriott JB
Curr Opin Investig Drugs; 2003 Jun; 4(6):667-74. PubMed ID: 12901224
[TBL] [Abstract][Full Text] [Related]
7. Anti-angiogenic function of tocotrienol.
Miyazawa T; Shibata A; Nakagawa K; Tsuzuki T
Asia Pac J Clin Nutr; 2008; 17 Suppl 1():253-6. PubMed ID: 18296349
[TBL] [Abstract][Full Text] [Related]
8. [Novel angiogenesis inhibitors for molecular target therapy of cancer].
Osada H; Kakeya H
Nihon Rinsho; 2004 Jul; 62(7):1257-63. PubMed ID: 15283141
[TBL] [Abstract][Full Text] [Related]
9. Angiogenesis: a therapeutic target in arthritis.
Walsh DA; Haywood L
Curr Opin Investig Drugs; 2001 Aug; 2(8):1054-63. PubMed ID: 11892913
[TBL] [Abstract][Full Text] [Related]
10. Small molecules in anti-angiogenic therapy.
Giavazzi R; Nicoletti MI
Curr Opin Investig Drugs; 2002 Mar; 3(3):482-91. PubMed ID: 12054101
[TBL] [Abstract][Full Text] [Related]
11. Angiogenesis and its inhibition: potential new therapies in oncology and non-neoplastic diseases.
Billington DC
Drug Des Discov; 1991 Nov; 8(1):3-35. PubMed ID: 1725722
[TBL] [Abstract][Full Text] [Related]
12. [VEGF, anti-vEGF and diseases].
Corvol P
Bull Acad Natl Med; 2008 Feb; 192(2):289-300; discussion 300-2. PubMed ID: 18819684
[TBL] [Abstract][Full Text] [Related]
13. Targeting angiogenesis in head and neck cancer.
Seiwert TY; Cohen EE
Semin Oncol; 2008 Jun; 35(3):274-85. PubMed ID: 18544442
[TBL] [Abstract][Full Text] [Related]
14. [Role of the vascular component in growth of solid tumors: a historical review].
Ribatti D; Vacca A
Ann Ital Med Int; 1994; 9(2):92-5. PubMed ID: 7522501
[TBL] [Abstract][Full Text] [Related]
15. Angiogenesis: state of the art.
Han ZC; Liu Y
Int J Hematol; 1999 Aug; 70(2):68-82. PubMed ID: 10497845
[TBL] [Abstract][Full Text] [Related]
16. Role of the microenvironment in tumor growth and in refractoriness/resistance to anti-angiogenic therapies.
Shojaei F; Ferrara N
Drug Resist Updat; 2008 Dec; 11(6):219-30. PubMed ID: 18948057
[TBL] [Abstract][Full Text] [Related]
17. A new family of angiogenic factors.
Martínez A
Cancer Lett; 2006 May; 236(2):157-63. PubMed ID: 15927357
[TBL] [Abstract][Full Text] [Related]
18. Role of hematopoietic lineage cells as accessory components in blood vessel formation.
Takakura N
Cancer Sci; 2006 Jul; 97(7):568-74. PubMed ID: 16827795
[TBL] [Abstract][Full Text] [Related]
19. Anti-angiogenic gene therapy for cancer (review).
Isayeva T; Kumar S; Ponnazhagan S
Int J Oncol; 2004 Aug; 25(2):335-43. PubMed ID: 15254730
[TBL] [Abstract][Full Text] [Related]
20. Angiotherapeutics from natural products: from bench to clinics?
Bernas G
Clin Hemorheol Microcirc; 2003; 29(3-4):199-203. PubMed ID: 14724342
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
